A New Collaboration to Advance Cell Therapy for Brain Cancer

To accelerate cellular therapies for the most deadly brain cancer in adults – glioblastoma multiforme (GBM) – Alliance for Cancer Gene Therapy, Cancer Research Institute (CRI) and Parker Institute for Cancer Immunotherapy (PICI) are collaborating to tackle the many challenges of this complex disease.

CRI, PICI and ACGT share many of the same goals, and through this partnership the three organizations are taking a collaborative approach to gain insights into the most difficult issues in treating GBM. By combining cellular therapy expertise and cutting-edge technologies to analyze brain tumor tissue, the program aims to make progress against GBM – a cancer that in the last 30 years has seen few treatment advances and continues to have extremely unfortunate outcomes for patients.

The focus is based on the incredible progress of cell and gene therapies in other cancers and ACGT’s mission to bring this same success to the most difficult to treat solid tumors. This coordinated and collaborative initiative will generate a never before available biological understanding of GBM. In addition, it will provide researchers with a nationwide clinical infrastructure and access to the largest patient tissue samples database, enabling research teams to make significant progress on multiple levels.

GBM is a powerful adversary with a microenvironment that potently limits the effectiveness of therapies that have shown progress in other cancers. No single approach, no one entity, no individual therapy has been able to successfully meet the complex challenges of GBM. With aggressive standard therapies, including surgical resection, radiation and chemotherapy, the median survival for patients with GBM is just 20 months. It is extremely difficult for treatments to successfully cross the blood brain barrier and penetrate the tumor with enough volume to impact the disease and to sustain a therapeutic effect. In addition, GBM tumors are extremely heterogeneous – a treatment that works in one part of a tumor may not work in another or may even amplify the cancer.

“GBM is one of the most challenging of solid tumors from a treatment perspective. Cures are going to come by pushing the boundaries of technology, drug development, clinical trial design and breaking down silos that classically separate bioinformatics, technology, basic research and clinicians. PICI is committed to partner with others that understand that collaboration is the key to change,” said Samantha Bucktrout, Senior Director of Research and Development, Parker Institute for Cancer Immunotherapy.

The goal is to harmonize research efforts, standardize reporting methodologies and use cutting edge analytical tools to lay the groundwork for novel and combinatorial clinical trials across multiple institutions and research networks.

By integrating teams of the best researchers and enabling them to increase the quantity and quality of data generated through tissue analysis and clinical trials, all stakeholders could learn faster and learn more about what makes GBM such a complex killer in the quest to l develop therapeutic strategies to bring patients new hope.

“When tackling hard-to-treat cancers like glioblastoma multiforme, coordination and collaboration are critical to the success of any efforts to bring effective cell and gene therapies to patients with this disease. By tapping the expertise of the extensive clinical cancer immunotherapy networks created by the Cancer Research Institute and the Parker Institute for Cancer Immunotherapy, CRI and PICI, together with ACGT, hope to accelerate discovery and development of improved immunotherapies to treat GBM,” said Jill O’Donnell-Tormey, Ph.D., CEO and Director of Scientific Affairs, Cancer Research Institute.

The first phase focuses on analyzing patient samples to inform first-in-human clinical trials at City of Hope; Stanford University; University of California, San Francisco (UCSF); University of California, Los Angeles (UCLA). To further contribute to these coordinated efforts, the partnership has engaged the experience and expertise of leading GBM and cell and gene therapy visionaries, including ACGT Research Fellows Carl H. June, MD, and Crystal Mackall, MD. ACGT Scientific Advisory Council member Noriyuki Kasahara, MD, PhD, principal investigator at the Brain Tumor Center at UCSF, will represent ACGT within the partnership’s joint steering committee.

“This collaboration with PICI and CRI goes to the heart of ACGT’s mission – addressing the toughest challenges in cancer research by enabling the best scientific minds to work together – advancing our understanding of glioblastoma and developing powerful cell and gene therapies that will significantly change the outlook for patients,” said Barbara Lavery, Chief Program Officer, Alliance for Cancer Gene Therapy.

Donations to ACGT will further enable us to collaborate with CRI and PICI on this important effort to bring the power of cell and gene therapy to patients with GBM – patients who may not see new treatment breakthroughs without this help.

ACGT’s first-year investment of $750,000 is directly funding tissue analysis using multiplexed ion beam imaging (MIBI) technology, powering the partnership’s vision and enabling research teams to put their plans into motion.